DK0489032T3 - Hydroxaminsyre-baserede kollagenaseinhibitorer - Google Patents

Hydroxaminsyre-baserede kollagenaseinhibitorer

Info

Publication number
DK0489032T3
DK0489032T3 DK90911398.7T DK90911398T DK0489032T3 DK 0489032 T3 DK0489032 T3 DK 0489032T3 DK 90911398 T DK90911398 T DK 90911398T DK 0489032 T3 DK0489032 T3 DK 0489032T3
Authority
DK
Denmark
Prior art keywords
hydroxamic acid
collagenase inhibitors
based collagenase
disease
involving
Prior art date
Application number
DK90911398.7T
Other languages
English (en)
Inventor
Alan Hornsby Davidson
Michael John Crimmin
Colin Campion
Jonathan Philip Dickens
Original Assignee
British Bio Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Bio Technology filed Critical British Bio Technology
Application granted granted Critical
Publication of DK0489032T3 publication Critical patent/DK0489032T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK90911398.7T 1989-08-24 1990-07-20 Hydroxaminsyre-baserede kollagenaseinhibitorer DK0489032T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898919251A GB8919251D0 (en) 1989-08-24 1989-08-24 Compounds

Publications (1)

Publication Number Publication Date
DK0489032T3 true DK0489032T3 (da) 1995-01-30

Family

ID=10662057

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90911398.7T DK0489032T3 (da) 1989-08-24 1990-07-20 Hydroxaminsyre-baserede kollagenaseinhibitorer

Country Status (16)

Country Link
US (2) US5453438A (da)
EP (1) EP0489032B1 (da)
JP (1) JP2871849B2 (da)
KR (1) KR927003624A (da)
AT (1) ATE111443T1 (da)
AU (1) AU639706B2 (da)
CA (1) CA2064786A1 (da)
DE (1) DE69012575T2 (da)
DK (1) DK0489032T3 (da)
ES (1) ES2063975T3 (da)
FI (1) FI920771A7 (da)
GB (1) GB8919251D0 (da)
NO (1) NO920702L (da)
NZ (1) NZ235050A (da)
TW (1) TW202456B (da)
WO (1) WO1991002716A2 (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827308D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
US5268384A (en) * 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
EP0520573A1 (en) * 1991-06-27 1992-12-30 Glaxo Inc. Cyclic imide derivatives
WO1993020047A1 (en) * 1992-04-07 1993-10-14 British Bio-Technology Limited Hydroxamic acid based collagenase and cytokine inhibitors
GB9211706D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5326760A (en) * 1992-06-29 1994-07-05 Glaxo, Inc. Aminobutanoic acid compounds having metalloprotease inhibiting properties
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
ATE169621T1 (de) * 1993-03-16 1998-08-15 British Biotech Pharm Hydroxamsaeurederivate als metalloproteinase inhibitoren
JPH08500124A (ja) * 1993-04-27 1996-01-09 セルテック セラピューティックス リミテッド メタロプロテイナーゼインヒビターとしてのペプチジル誘導体
GB9308695D0 (en) * 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
ES2075797B1 (es) * 1993-08-18 1996-05-16 British Bio Technology Derivados de acidos hidroxamicos terapeuticamente activos, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y el uso de dichos compuestos en medicina.
ES2075798B1 (es) * 1993-08-18 1996-03-01 British Bio Technology Derivados de aminoacidos naturales como inhibidores de metaloproteinasas, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y el uso de dichos compuestos en medicina.
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
BR9506535A (pt) * 1994-01-20 1997-09-16 British Biotech Pharm Inibidores de metaloproteinases
GB9501737D0 (en) * 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
US5831004A (en) * 1994-10-27 1998-11-03 Affymax Technologies N.V. Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
US5840698A (en) * 1994-10-27 1998-11-24 Affymax Technologies N.V. Inhibitors of collagenase-1 and stormelysin-I metalloproteases, pharmaceutical compositions comprising same and methods of their use
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5639746A (en) * 1994-12-29 1997-06-17 The Procter & Gamble Company Hydroxamic acid-containing inhibitors of matrix metalloproteases
US5919940A (en) * 1995-01-20 1999-07-06 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
ATE205184T1 (de) 1995-11-23 2001-09-15 British Biotech Pharm Metalloproteinase inhibitoren
CZ62799A3 (cs) * 1996-08-28 1999-07-14 The Procter & Gamble Company Heterocyklické metaloproteázové inhibitory
IL128667A (en) * 1996-08-28 2002-04-21 Procter & Gamble Spirocyclic metroprotease inhibitors and pharmaceutical preparations containing them
HUP0000130A2 (hu) * 1996-08-28 2000-06-28 The Procter And Gamble Co. 1,3-Heterociklusos fémproteáz inhibitorok
KR20000035920A (ko) 1996-08-28 2000-06-26 데이비드 엠 모이어 헤테로고리성 메탈로프로테아제 저해제
CZ63699A3 (cs) * 1996-08-28 1999-07-14 The Procter & Gamble Company Sloučeniny na bázi amidů kyseliny fosfinové jako inhibitory metaloprotáz mezibuněčné hmoty, způsob jejich přípravy a jejich použití jako léčiv
DE69714056T2 (de) * 1996-09-10 2003-02-27 British Biotech Pharmaceuticals Ltd., Cowley Cytostatische hydroxamsäurederivate
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
US5840974A (en) * 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
IL134273A0 (en) 1997-07-31 2001-04-30 Procter & Gamble Acyclic metalloprotease inhibitors
GB9810464D0 (en) * 1998-05-16 1998-07-15 British Biotech Pharm Hydroxamic acid derivatives
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
TR200102523T2 (tr) 1999-03-03 2002-02-21 The Procter & Gamble Company Alkenil ve alkinil içeren metaloproteaz inhibitörleri
JP2003506438A (ja) * 1999-08-10 2003-02-18 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド 抗菌剤
GB9929527D0 (en) * 1999-12-14 2000-02-09 Smithkline Beecham Plc Novel compounds
US6797820B2 (en) * 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
EP1406893B1 (en) 2001-06-15 2007-04-18 Vicuron Pharmaceuticals, Inc. Pyrrolidine bicyclic compounds
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105789A (en) * 1976-05-10 1978-08-08 E. R. Squibb & Sons, Inc. Carboxyalkylacylamino acids
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4499079A (en) * 1982-11-18 1985-02-12 E. R. Squibb & Sons, Inc. Carboxy and substituted carboxy alkanoyl and cycloalkanoyl peptides
US4496540A (en) * 1982-12-30 1985-01-29 Biomeasure, Inc. Therapeutic compounds
JPS6115840A (ja) * 1984-07-03 1986-01-23 Microbial Chem Res Found 免疫賦活剤
US4743587A (en) * 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes

Also Published As

Publication number Publication date
FI920771A0 (fi) 1992-02-21
AU6045490A (en) 1991-04-03
JP2871849B2 (ja) 1999-03-17
NO920702D0 (no) 1992-02-21
AU639706B2 (en) 1993-08-05
NZ235050A (en) 1991-12-23
WO1991002716A3 (en) 1991-06-27
KR927003624A (ko) 1992-12-18
DE69012575T2 (de) 1995-03-30
ATE111443T1 (de) 1994-09-15
CA2064786A1 (en) 1991-02-25
FI920771A7 (fi) 1992-02-21
DE69012575D1 (de) 1994-10-20
EP0489032B1 (en) 1994-09-14
ES2063975T3 (es) 1995-01-16
WO1991002716A2 (en) 1991-03-07
TW202456B (da) 1993-03-21
GB8919251D0 (en) 1989-10-04
NO920702L (no) 1992-04-23
US5910609A (en) 1999-06-08
JPH05501864A (ja) 1993-04-08
EP0489032A1 (en) 1992-06-10
US5453438A (en) 1995-09-26

Similar Documents

Publication Publication Date Title
DK0489032T3 (da) Hydroxaminsyre-baserede kollagenaseinhibitorer
DE69734661D1 (de) Foerderung der wundheilung durch chemisch modifizierte tetracycline
ES2063334T3 (es) Inhibidores de la colagenasa basados en el acido hidroxamico.
ATE191472T1 (de) Neuartige metalloprotease-inhibitoren und diese enthaltende pharmazeutische zusammensetzungen
DE50002293D1 (de) Verwendung von csf-1-inhibitoren
DK1030836T3 (da) Hydroxam- og carboxylsyrederivater der har MMP- og TNF-inhiberende aktivitet
ES2148229T3 (es) Eteres y tioeteres en la posicion 17 de 4-aza-esteroides.
CY1105501T1 (el) Συνδυασμοι φαρμακων (π.χ. chlorpromazine και pentamidine) για την αντιμετωπιση νεοπλαστικων διαταραχων
CY1110521T1 (el) Υποκατεστημενα ινδολια για τη διαμορφωση της nfkb-ενεργοτητας
NO911962D0 (no) Hydroksaminsyrebaserte kollagenaseinhibitorer.
DE60138549D1 (de) Topische gel-abgabesysteme zur behandlung von hauterkrankungen
TR200202738T2 (tr) Endotelin ile ilgili hastalıkların tedavisinde kullanılan sülfanoamidler
EP0975349A4 (en) Serine proteinase inhibitory activity by hydrophobic tetracycline
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
EA199900542A1 (ru) Соединения сульфоновой кислоты или сульфониламино-n-(гетероаралкил)-азагетероциклиламида
EA200000921A1 (ru) Антагонисты рецептора витронектина
EA199700381A1 (ru) Диароматические соединения пропинила или диенила, промежуточные соединения, фармацевтические и косметические композиции на основе указанных соединений и применение косметических композиций
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE69419954D1 (de) Arzneimittel zur Behandlung von Hauterkrankungen
DK0588477T3 (da) Medicinsk præparat omfatende TCF-11
RU94014833A (ru) Средство для лечения дегенеративных заболеваний суставов и околосуставных тканей
PT1115375E (pt) Utilizacao de pelo menos um derivado do acido 10-hidroxi-2-decenoico numa composicao destinada a favorecer a descamacao da pele
DE60126591D1 (de) In-vitro-Verwendung von Astaxanthin zur Vorbehandlung von Zellen vor UV-Bestrahlung zwecks Hemmung der Aktivierung von NF-KB
ES2120944T3 (es) Derivados de antraciclina con actividad citostatica.
DE69828638D1 (de) Hydroxam- und carbonsäurederivate mit mmp- und tnf-hemmender aktivität